REVIEW Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs #RNAi #siRNA #antisense #oligonucleotide $ALNY $IONS $ARWR $DRNA $RGLS $GERN $AKCAhttps://t.co/ienDpFManf pic.twitter.com/X5U5xZGHTl— Oligotherapeutics (@OTSociety) January 8, 2018
5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology https://t.co/5F2x7G3DCM— Marta Filizola (@martafilizola) February 2, 2018
Trajectories of Injectable Cancer Drug Costs After Launch in the United States@drdgoldstein in @JCO_ASCO— Anirban Maitra (@Aiims1742) February 2, 2018
"Regardless of competition or supplemental indications, there is a steady increase in costs"
This issue will never get old or irrelevant. https://t.co/Dp34InZ4r9 pic.twitter.com/MkCz16yxMn
The more the data comes out on coffee, the better it looks :-) ☕️— Eric Topol (@EricTopol) February 6, 2018
Biggest review yet (w/ caveats articulated) https://t.co/MDQF4VQao3 @AnnualReviews @HarvardChanSPH @NNEdPro pic.twitter.com/F4fmXPHjU8
The kinetic roots of CRISPR-Cas targeting https://t.co/cobDpOKWd9— Cell Reports (@CellReports) February 9, 2018